ThermoBreast project successfully evaluated by the European Union The European Union has announced that the ThermoBreast proposal has been successfully evaluated and that they will be investing 12.12 million euros...
University Hospital Heidelberg, Department of Obstenetrics and Gynecology (UKHD)
The University Hospital Heidelberg is one of the oldest and largest medical institutions in Europe. It especially reknown for innovative cancer care and cancer research, together with its partner insitutions the National Center for Tumor Diseases and the German Cancer Research Center in Heidelberg.
Role within ThermoBreast
For the EU Horizon project ThermoBreast, the design and conduction of the clinical trial will be led by clinical researchers from the University Hospital Heidelberg.
TUM brings significant expertise in optoacoustic imaging, having developed prototypes for animal and clinical research imaging. They also have advanced computational facilities, with expertise in classical and artificial intelligence, which will be available to the project. With more than 300 peer–reviewed publications on optical imaging, and fundamental developments in the field of optoacoustics, the TUM team offers world–leading ability for medical imaging technology innovation, prototyping and research.
UMCG is an internationally renowned research center focused on promoting healthy living. Their department is composed of experts from different disciplines, including medicine, nursing, psychology, sociology, epidemiology, and public health. UMCG is committed to conducting collaborative and interdisciplinary research, to better understand the determinants of health and well–being, and to develop innovative solutions to improve health and health care. Their research focuses on developing and evaluating interventions that improve health outcomes and reduce health disparities as well as ensuring their research is translated into meaningful policy changes and evidence–based practice.
Role within ThermoBreast
In the ThermoBreast project, UMCG is in the lead for the work package Evaluation. UMCG is primarily in charge of the health technology assessment and cost-effectiveness analysis of Thermography screening compared with other breast cancer screening strategies. Moreover, UMCG supports the investigation of reimbursement schemes in different European countries regarding their national and local reimbursement conditions.
The Vrije Universiteit Brussel (VUB) is an internationally oriented university with eight faculties in Brussels, the heart of Europe. Through tailor-made high quality research and education, VUB contributes in an active and committed way to a better society for tomorrow. The SMIT (Studies in Media innovation and Technology) research group, conducts user research, policy research and business analysis, making use of both qualitative and quantitative methodologies.
Role in ThermoBreast:
Our team will focus on explainability and trustworthiness of ThermoBreast screening approach, enhancing the quality of the user experience during screening and follow up of both patients and clinicians. We will study and develop methods to assess the ethical aspect (privacy, autonomy, transparency, bias, …) of this AI driven solution and their social impact.
CPE is an advocacy organisation based in Belgium that advocates for the rights and needs of cancer patients and their families. They are dedicated to raising awareness and understanding of the challenges faced by cancer patients and their families and strive to ensure that all cancer patients and their families have access to the best possible treatment and care, and to build a supportive environment for them. CPE works with healthcare professionals, policy makers, and other stakeholders to develop and advance policies that promote patient rights, access to care, and research for better treatments. They also provide resources and support for cancer patients and their families, to help them navigate through the healthcare system and cope with the challenges of living with cancer.
Role in ThermoBreast
CPE ensures the involvement of patients at different stages (prevention/monitoring) and needs:
– Elucidation of patient needs
– Analysis of ethical, and social aspects applicable to ThermoBreast
– Communication
– Dissemination
In detail CPE:
– Collects stakeholder requirements, recommendations, and policy expectations in workshops and surveys
– Gathers end-user perspectives, i.e., from patients with surveys and focus groups
– Prepares a White Paper, which will include recommendations on future guidelines and international regulations based on results from the clinical validation
– Organises the final event at the European Parliament
– Explores the required explainability of the ThermoBreast screening process and modality to enable a trustworthy solution. Create (user journey) scenarios with personas (one for each relevant stakeholder group represented by CPE)
– Raises awareness of and gains interest in the project using CPEs and other participants’ established networks and social media channels
– Prepares regular newsletters and press releases
– Distributes printed materials to the project stakeholders
IGR is a leading research center in France, dedicated to advancing the field of medical imaging. The department is composed of a team of experienced radiologists, physicists and engineers, who are dedicated to providing the highest quality of medical imaging services, with the latest imaging technologies and equipment. The department is committed to developing new imaging techniques, as well as improving existing ones, in order to provide more accurate diagnoses and treatments. They collaborate with researchers from a wide range of disciplines to advance the field of medical imaging and to improve patient care.
KC is a leading healthcare provider in Lithuania, dedicated to providing high quality medical services to their patients. The hospital is equipped with advanced medical technology and equipment, staffed with experienced medical professionals. They offer a wide range of medical services, including general medicine, surgery, diagnostics, and emergency care. The hospital strives to provide the best possible care and treatment, to ensure that all their patients are given access to the best possible healthcare. They are committed to providing the highest levels of care and service, and to improving the quality of life of their patients and their families.
accelCH is a Swiss SME that assists research institutions and companies in EU project management and the dissemination and exploitation of project results. It is specialised in European research and innovation support initiatives, such as Horizon Europe and the SME focused Eurostars programme. accelCH’s multi-disciplinary and highly qualified staff has over 25 years of experience in EU and national funded projects in Health, Biochemistry, Energy, ICT, Materials and other areas.
Since its foundation in 2008, accelCH has collaborated with more than 1,000 organisations in Europe and beyond, starting with the 7th Framework Programme and continuing into Horizon 2020 and Horizon Europe. accelCH is ISO 9001 certified and internationally accredited by IQnet and members of the Swiss Association for Quality and Management Systems.
Role within ThermoBreast
accelCH leads the work package on dissemination, exploitation, and public engagement. This includes the development of materials and content, monitoring and evaluating the implementation of dissemination and communication activities. Furthermore, accelCH supports ThermoMind in operational management in all aspects related to governance, administration, reporting, finances, contracts, and innovation management.
ThermoBreast project successfully evaluated by the European Union The European Union has announced that the ThermoBreast proposal has been successfully evaluated and that they will be investing 12.12 million euros...
Official start of ThermoBreast on 1 January 2023 ThermoBreast, an innovative and non-contact breast cancer detection and patient monitoring system, is set to revolutionise the way breast cancer is detected....
Kick-off meeting to be hosted by coordinator, ThermoMind Ltd. in February 2023 ThermoMind Ltd., the leader of the ThermoBreast EU-funded project, hosted a kick-off meeting on the 6th and 7th...
Project Coordinator ThermoMind Ltd. receives the 2023 Next-Gen Women Entrepreneurship Award The ThermoBreast project coordinators Larisa Adamyan, Najeeb Ayoub, and the ThermoMind team were honoured with the Next-Gen Women Entrepreneurship...
The first Vision One system at Klinik Sankt Elisabeth in Heidelberg successfully installed and set up for patient recruitment! ThermoBreast, led by ThermoMind, has reached a significant milestone – the...
The first cluster meeting “Prevention including Screening” under the EU Cancer Mission, San Sebastian, Spain The meeting was a great opportunity for all projects to review the scope of their...
Milestone Reached: First Patients Taking Part in the ThermoBreast Clinical Study in Heidelberg, Germany We are delighted to announce that we have the first patients taking part in our ThermoBreast...
The Vision One device Successfully Deployed at Assuta Medical Centers in Haifa, Israel The ThermoBreast team is proud to announce the successful deployment of ThermoMind’s innovative Vision One device at...
ThermoBreast and “Prevention and Early Detection (Screening)” Cluster Update: Conclusions of the First Year The fight against cancer is a constant battle, and one that requires collaborative efforts. That is...
"Our mission is to improve the survival rate of breast cancer patients by effectively detecting cancer in early stages in women of all age groups and breast densities using a risk-free and non-contact screening modality. Our cost-efficient method will make it possible to start regular screening of women from the age of 18 years, facilitate follow-up tests for better patient monitoring and use ThermoBreast as a supplementary diagnostic modality."
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them (grant agreement no. 101096329).
Swiss participants in this project are supported by the Swiss State Secretariat for Education, Research and Innovation (contract no. 22.00518).
